Lantus Manufacturer Copay Program: How to Cut Your Insulin Glargine Costs in 2026

How the Sanofi Valyou Savings Program Works

The Valyou Savings Program is Sanofi's broadest access initiative for Lantus. It sets a flat monthly price of $35 for up to 10 boxes of pens or 10 vials per fill, and it applies whether you carry commercial insurance, are uninsured, or are underinsured. The program launched in 2024 and remains active in 2026.

Enrollment takes less than five minutes. You can sign up at lantus.com or by calling Sanofi directly at 1-888-SANOFI (1-888-726-6343). Once registered, you receive a savings card that your pharmacy processes at the point of sale. There are no income requirements and no prior authorization steps for the Valyou card itself.

One key restriction: the Valyou Savings Program does not apply to patients covered by Medicare, Medicaid, TRICARE, or any other federally funded insurance program. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-insured patients. If you have Medicare Part D, a different $35 cap already exists under the Inflation Reduction Act of 2022, which limits monthly insulin copays to $35 for all Part D enrollees [1].

For commercially insured patients who already have relatively low copays, Sanofi also offers a traditional copay card that covers up to $150 per fill. This card stacks with your insurance benefit, meaning the manufacturer picks up whatever your plan does not. Patients with high-deductible health plans often find more value in the Valyou flat-rate program, while those with established formulary coverage may prefer the copay card.

What Lantus Actually Costs Without Help

A single 10 mL vial of Lantus (1,000 units total) carries a wholesale acquisition cost (WAC) near $300. Retail cash prices vary by pharmacy but typically land between $270 and $350 per vial. A patient using 40 units daily needs roughly 1.2 vials per month, putting unassisted monthly costs above $300.

That figure has drawn intense scrutiny. A 2018 analysis in JAMA Internal Medicine found that the price of insulin glargine increased by 64% between 2014 and 2017, far outpacing inflation [2]. The American Diabetes Association's 2024 Standards of Care explicitly recommend that clinicians "assess financial barriers to insulin adherence at every visit" because cost-related nonadherence contributes to preventable hospitalizations [3].

The introduction of biosimilar and interchangeable insulin glargine products has begun to compress prices at the pharmacy level. Semglee (insulin glargine-yfgn), approved by the FDA as the first interchangeable biosimilar insulin in 2021, carries a list price roughly 65% below brand Lantus [4]. Basaglar (insulin glargine), marketed by Eli Lilly, and Rezvoglar (insulin glargine-aglr) offer additional alternatives. Your prescriber can switch you to any of these without a new prior authorization in most states, provided the product holds interchangeable status.

Sanofi Patient Connection: Free Lantus for Qualifying Patients

Sanofi's Patient Assistance Program (PAP), branded as Patient Connection, provides Lantus at no cost to patients who meet all three criteria: (1) U.S. residency, (2) no prescription drug coverage or a coverage gap that leaves Lantus unaffordable, and (3) household income at or below 400% of the federal poverty level (approximately $62,400 for a single individual in 2026).

Applications require a prescriber signature and proof of income. Processing typically takes two to four weeks. Once approved, Lantus ships directly to your physician's office or to a specialty pharmacy, depending on the program cycle. Approval periods last 12 months and must be renewed annually.

According to Sanofi's 2024 corporate social responsibility report, Patient Connection served over 125,000 patients across all Sanofi insulins in the prior calendar year. The program is separate from Valyou and can be used by patients who do not qualify for the savings card (including some government-insured patients during coverage gaps). Application forms are available at sanofipatientsupport.com or by calling the same 1-888-SANOFI line [5].

How Insurance Formulary Tiers Affect Your Lantus Cost

Where Lantus sits on your insurer's formulary determines your baseline copay before any manufacturer assistance kicks in. Most commercial plans classify insulin glargine products into one of four tiers:

Tier 1 (Preferred generic): Rarely applies to Lantus itself but may apply to authorized generic insulin glargine, which Sanofi released in 2024 at a list price of $92 per vial. Copays here typically range from $0 to $15.

Tier 2 (Preferred brand): Some plans place Lantus here, especially if the plan has a preferred relationship with Sanofi. Copays generally run $25 to $50.

Tier 3 (Non-preferred brand): The most common tier for brand Lantus on plans that prefer Basaglar or a biosimilar. Copays climb to $50 to $100, and coinsurance models may charge 25-40% of the negotiated price.

Specialty tier: Unusual for Lantus but possible on high-deductible plans. Out-of-pocket costs here can exceed $200 per fill until the deductible is met.

A 2023 study in Diabetes Care examined 11.8 million commercially insured adults with type 2 diabetes and found that patients facing out-of-pocket insulin costs above $50 per month were 1.77 times more likely to abandon their prescription at the pharmacy counter compared with those paying under $10 [6]. That finding underscores why checking your formulary placement before filling is not optional. Call the number on the back of your insurance card, or use your insurer's online formulary lookup tool, to confirm Lantus's tier and whether a biosimilar carries a lower cost-share.

If your plan's preferred product is Basaglar or Semglee, switching to that product may reduce your copay without requiring manufacturer assistance at all. The American Association of Clinical Endocrinology (AACE) 2024 consensus statement notes that biosimilar and interchangeable insulin glargine products have "comparable efficacy and safety profiles" to the reference product and support substitution when cost is a barrier [7].

Medicare and Medicaid: Different Rules Apply

The Inflation Reduction Act (IRA) capped Medicare Part D insulin copays at $35 per month beginning January 1, 2023. This statutory cap applies to all insulin products covered under Part D, including Lantus, and it eliminates the coverage gap ("donut hole") for insulin [1]. If you are on Medicare, you do not need a manufacturer copay card. Your pharmacy should automatically apply the $35 cap.

For Medicare Advantage plans, the same $35 cap applies to insulin obtained through the plan's Part D benefit. Some MA plans have gone further, offering $0 copays on preferred insulin products as a supplemental benefit. Check your plan's Evidence of Coverage document or call the plan directly.

Medicaid coverage varies by state. Most state Medicaid programs cover at least one long-acting insulin glargine product with no copay or a nominal copay of $1 to $3. However, preferred product lists differ. Texas Medicaid, for example, prefers Basaglar, while New York Medicaid covers Lantus as preferred. If your state's Medicaid program requires a non-preferred prior authorization for Lantus, your prescriber can submit a formulary exception request citing clinical necessity.

The Centers for Disease Control and Prevention (CDC) reports that 37.3 million Americans have diabetes, and approximately 8.4 million insulin users face cost as a "significant barrier" to adherence [8]. Federal policy changes have reduced but not eliminated access gaps, particularly for uninsured patients who fall outside both Medicaid eligibility and the IRA's Medicare protections.

Pharmacy-Level Strategies That Stack With Manufacturer Programs

Beyond manufacturer and insurance pathways, several pharmacy-level strategies can reduce what you pay for insulin glargine. These approaches work independently or alongside the Valyou card.

Authorized generic Lantus. Sanofi's own authorized generic insulin glargine carries the same formulation and device as brand Lantus but lists at roughly $92 per vial. Some pharmacies stock it automatically when the generic is cheaper than the brand copay. Ask your pharmacist whether the authorized generic is available.

340B pricing. Federally qualified health centers (FQHCs), certain hospital outpatient pharmacies, and other 340B-covered entities purchase Lantus at steep discounts. If you receive care at a 340B-eligible facility, your out-of-pocket cost could be substantially below retail. The Health Resources and Services Administration (HRSA) maintains a database of 340B-covered entities.

State insulin price caps. As of 2026, at least 25 states have enacted insulin copay caps for state-regulated commercial plans, typically at $25 to $50 per 30-day supply. These caps do not apply to self-funded employer plans (governed by ERISA), but they cover a significant share of the individual and small-group market. Check your state insurance department's website for current limits.

Mail-order pharmacy. Many insurers offer 90-day supplies through mail-order at two times the 30-day copay rather than three times. For a patient paying $35 per month through Valyou, this does not help. But for a patient with a $40 commercial copay, a 90-day mail-order fill at $80 saves $40 per quarter.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "No person with diabetes should ever have to ration insulin because of cost. The tools to eliminate insulin affordability barriers exist today; the challenge is making sure every patient knows about them" [9].

Step-by-Step: Enrolling in the Valyou Savings Program

Getting the $35 price requires five steps, each of which takes minutes.

1. Confirm eligibility. You must not be enrolled in Medicare, Medicaid, TRICARE, or another federal or state healthcare program for outpatient drug coverage. Commercially insured patients and uninsured patients both qualify.

2. Visit lantus.com or call 1-888-SANOFI. Select the Valyou Savings Program option. You will need your name, date of birth, and prescription details.

3. Receive your savings card. Sanofi issues a digital or physical card with a BIN, PCN, and group number. Save this information in your phone.

4. Present the card at the pharmacy. Hand the card to your pharmacist alongside your prescription. The pharmacist processes it as a secondary payer (or primary if you are uninsured). The system adjudicates in real time.

5. Refill monthly. The card works for every fill throughout the calendar year. Re-enrollment is required each January. Sanofi typically sends reminders by email or text if you have opted in.

If the pharmacy rejects the card, the most common cause is an incorrect BIN or PCN entry. Ask the pharmacist to re-enter the numbers manually. If the issue persists, call the number on the back of the savings card for real-time pharmacy help desk support.

Biosimilar and Interchangeable Alternatives to Lantus

Biosimilar competition has reshaped insulin glargine pricing. Three alternatives to brand Lantus are now available in the United States:

Semglee (insulin glargine-yfgn), manufactured by Viatris/Biocon, holds FDA interchangeable status. This designation means pharmacists in all 50 states can substitute Semglee for Lantus without prescriber intervention, similar to how generic drugs are dispensed. Semglee's list price is approximately $100 per vial, and Viatris offers its own savings programs [4].

Basaglar (insulin glargine), manufactured by Eli Lilly, is classified as a follow-on biologic (not formally interchangeable under the BPCIA pathway). It has been on the market since 2016 and carries extensive real-world safety data. A retrospective cohort study published in Diabetes, Obesity and Metabolism (N=19,372) found no statistically significant difference in HbA1c reduction or hypoglycemia rates between Basaglar and Lantus over 12 months of use [10].

Rezvoglar (insulin glargine-aglr), manufactured by Eli Lilly under the Lilly Biosimilars portfolio, received FDA approval in 2021. It offers another option, particularly for plans that prefer Lilly products.

The Endocrine Society's 2024 clinical practice guideline on type 2 diabetes management recommends that "clinicians discuss biosimilar insulin options with patients when cost is a barrier to adherence," noting equivalent glycemic outcomes across products [11].

Switching between insulin glargine products does not require dose adjustment. The concentration (100 units/mL), onset (1 to 2 hours), and duration (up to 24 hours) are clinically equivalent. Your prescriber may write "insulin glargine" without specifying a brand, allowing the pharmacy to dispense whichever product offers the lowest cost under your coverage.

What to Do if You Are Rationing Insulin Right Now

Insulin rationing is a medical emergency. If you are skipping doses, splitting pens, or letting prescriptions lapse because of cost, take these steps today:

1. Call Sanofi at 1-888-726-6343 and request emergency supply. Sanofi and other insulin manufacturers have committed to providing short-term emergency insulin to patients in crisis.

2. Contact your prescriber's office and ask for samples. Most endocrinology and primary care offices keep Lantus SoloStar pens on hand from manufacturer sample programs.

3. Visit an FQHC. Federally qualified health centers are required to see patients regardless of ability to pay, and many carry 340B-priced insulin.

4. Apply for Patient Connection (the PAP) simultaneously. Even though processing takes two to four weeks, initiating the application now ensures coverage continuity.

A 2019 cross-sectional survey in Annals of Internal Medicine (N=1,164) reported that 25.5% of insulin users reported cost-related underuse in the prior year, with rationing more prevalent among uninsured adults (35.5%) and those with high-deductible plans (28.3%) [12]. These are not abstract numbers. Insulin rationing has caused documented cases of diabetic ketoacidosis and death.

The FDA's page on insulin provides a current list of all approved insulin products, biosimilars, and interchangeable designations, which can help you and your prescriber identify the most affordable option quickly [13].

Comparing All Lantus Savings Pathways: A Decision Guide

The best program for you depends on your insurance status and income. Here is how to match your situation to the right pathway:

Uninsured, income above 400% FPL: Use the Valyou Savings Program ($35/month). No income requirement.

Uninsured, income at or below 400% FPL: Apply for Patient Connection (free Lantus). Use Valyou as a bridge while the PAP application processes.

Commercially insured, high copay: Use the Valyou Savings Program ($35/month) or the copay card (up to $150 off), whichever yields the lower out-of-pocket cost. Your pharmacist can run both options and tell you which adjudicates lower.

Commercially insured, low copay: Use the copay card to reduce your existing copay toward $0. Valyou's flat $35 may actually be higher than your insured copay in this scenario.

Medicare Part D: The IRA $35 cap applies automatically. No manufacturer card needed or permitted.

Medicaid: Check your state's preferred drug list. Copays are typically $0 to $3. If Lantus requires prior authorization, ask your prescriber to submit an exception or switch to the state's preferred insulin glargine product.

All programs are subject to change. Verify current terms at lantus.com or by calling 1-888-SANOFI before each calendar year.